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Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson’s disease, dementia with Lewy bodies, and
multiple system atrophy. This provides an unprecedented opportunity to directly observe prodromal neurodegenerative states, and
potentially intervene with neuroprotective therapy. For future neuroprotective trials, it is essential to accurately estimate pheno-
conversion rate and identify potential predictors of phenoconversion. This study assessed the neurodegenerative disease risk and
predictors of neurodegeneration in a large multicentre cohort of iRBD. We combined prospective follow-up data from 24 centres
of the International RBD Study Group. At baseline, patients with polysomnographically-conﬁrmed iRBD without parkinsonism or
dementia underwent sleep, motor, cognitive, autonomic and special sensory testing. Patients were then prospectively followed,
during which risk of dementia and parkinsonsim were assessed. The risk of dementia and parkinsonism was estimated with
Kaplan-Meier analysis. Predictors of phenoconversion were assessed with Cox proportional hazards analysis, adjusting for age,
sex, and centre. Sample size estimates for disease-modifying trials were calculated using a time-to-event analysis. Overall, 1280
patients were recruited. The average age was 66.3  8.4 and 82.5% were male. Average follow-up was 4.6 years (range = 1–19
years). The overall conversion rate from iRBD to an overt neurodegenerative syndrome was 6.3% per year, with 73.5% converting
after 12-year follow-up. The rate of phenoconversion was signiﬁcantly increased with abnormal quantitative motor testing [hazard
ratio (HR) = 3.16], objective motor examination (HR = 3.03), olfactory deﬁcit (HR = 2.62), mild cognitive impairment (HR = 1.91–
2.37), erectile dysfunction (HR = 2.13), motor symptoms (HR = 2.11), an abnormal DAT scan (HR = 1.98), colour vision abnorm-
alities (HR = 1.69), constipation (HR = 1.67), REM atonia loss (HR = 1.54), and age (HR = 1.54). There was no signiﬁcant pre-
dictive value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apnoea, urinary dysfunction, orthostatic
symptoms, depression, anxiety, or hyperechogenicity on substantia nigra ultrasound. Among predictive markers, only cognitive
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variables were different at baseline between those converting to primary dementia versus parkinsonism. Sample size estimates for
deﬁnitive neuroprotective trials ranged from 142 to 366 patients per arm. This large multicentre study documents the high
phenoconversion rate from iRBD to an overt neurodegenerative syndrome. Our ﬁndings provide estimates of the relative predictive
value of prodromal markers, which can be used to stratify patients for neuroprotective trials.
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Introduction
The neurodegenerative synuclein aggregation disorders,
namely Parkinson’s disease, dementia with Lewy bodies,
and multiple system atrophy (MSA), all have a prodromal
interval; that is, a period during which neurodegenerative
symptoms/signs are present, but full clinical disease has not
yet developed (Berg et al., 2015). In the synucleinopathies,
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this interval is notably long, often exceeding a decade (Berg
et al., 2015). This provides an unprecedented opportunity
to provide potential neuroprotective therapy early, perhaps
even preventing the development of parkinsonism and
dementia.
Unlike many neurological diseases, whose prodromal
states are predominantly identiﬁed by abnormalities in the
same domain [e.g. mild cognitive impairment (MCI) is the
primary prodromal marker of Alzheimer’s disease], pro-
dromal synucleinopathy markers are notably diverse. In
addition to subtle motor signs, the potential prodromal
markers include autonomic abnormalities, olfactory loss,
cognitive changes, depression, anxiety, etc. (Goldman and
Postuma, 2014). Most are relatively non-speciﬁc, such that
the large majority of marker-positive subjects will never
develop disease. However, a notable exception is idiopathic
REM sleep behaviour disorder (iRBD).
RBD is a parasomnia in which the normal paralysis of
REM sleep is lost, such that patients ‘act out’ their dreams
(Schenck et al., 2013b; Hogl et al., 2018). Idiopathic RBD
[alternatively termed ‘isolated’ (Hogl et al., 2018) or ‘crypto-
genic’ RBD] has a prevalence of 1% over age 60 (Kang
et al., 2013; Haba-Rubio et al., 2018; Pujol et al., 2017),
although most do not present to medical attention.
Observational studies, generally from single centres, have
suggested that most patients with iRBD will eventually de-
velop a deﬁned neurodegenerative disease, almost always
diagnosed as synucleinopathy (Wing et al., 2012; Schenck
et al., 2013a; Iranzo et al., 2014; Arnulf et al., 2015;
Mahlknecht et al., 2015; Postuma et al., 2015a, d; Li
et al., 2017). In this context, RBD is likely related to neu-
rodegeneration in the pontine or medullary areas associated
with control of REM atonia (Valencia Garcia et al., 2018).
The latency from symptom onset to disease phenoconversion
(i.e. conversion from iRBD to deﬁned dementia with Lewy
bodies, Parkinson’s disease, or MSA) averages over 10 years
(Schenck et al., 2013b). Therefore, this implies that 1% of
the elderly population have a readily-diagnosable but often-
undetected early-stage neurodegenerative syndrome.
So far, most studies of phenoconversion risk and predictors
came from single centres, so whether this is seen across differ-
ent countries and different contexts remains unclear. In this
study, we combined the prospective experience of 24 centres
from the International RBD Study Group, to quantify the risk
of phenoconversion to deﬁned parkinsonism/dementia and to
test 21 potential predictors of phenoconversion.
Materials and methods
Subjects
For inclusion, all subjects had to have iRBD conﬁrmed on
polysomnogram according to American Academy of Sleep
Medicine Criteria (American Academy of Sleep Medicine and
Hauri, 2007), and be free of parkinsonism or dementia on
baseline neurological examination. Each patient had at least
one follow-up examination during which systematic assess-
ment for parkinsonism and dementia was performed. All pa-
tients gave written informed consent according to the
Declaration of Helsinki, and ethics approval was obtained
from the local institutional boards.
Baseline variables
Centres collected all available information on baseline vari-
ables, then followed patients prospectively. We did not require
that each variable be tested in each patient; rather, centres sent
results for all those variables that they systematically assessed.
Neither did we require that all variables be assessed with the
same technique, as centres had different testing protocols for
prodromal markers. For the analyses of hazard ratio (HR) in
with tests were categorized as abnormal or normal, each centre
deﬁned each variable as abnormal/normal according to their
own testing protocols, unless otherwise stated below. Detailed
numbers of patients assessed with each variable is provided in
Supplementary Table 1. Variables of interest and the assess-
ment methods used included:
(i) Standardized motor examination: tested with the Movement
Disorders Society Uniﬁed Parkinson Disease Rating Scale
(MDS-UPDRS) (Goetz et al., 2008). Either the 1987 UPDRS
or 2008 MDS-UPDRS version could be used. For stratiﬁcation
purposes, the cut-off score was 43 excluding action tremor
(Postuma et al., 2012).
(ii) Standardized motor symptoms: UPDRS/MDS-UPDRS Part II
(Fahn et al., 1987; Goetz et al., 2008).
(iii) Quantitative motor testing: tests included the alternate-tap test
(Nutt et al., 2000; Postuma et al., 2015c), Purdue PegBoard
(Desrosiers et al., 1995; Postuma et al., 2015c), 3-Metre
Timed-Up-and-Go (Podsiadlo and Richardson, 1991; Postuma
et al., 2015c), or Flamingo balance test (Barber et al., 2017). If
multiple tests were conducted in one centre, the majority had to
be abnormal to classify the testing as abnormal.
(iv) Olfaction: 12- or 40-item University of Pennsylvania Smell
Identiﬁcation Test (Doty et al., 1984) or Snifﬁn Sticks
(Hummel et al., 1997; Mahlknecht et al., 2015).
(v) Colour vision: Farnsworth-Munsell 100-Hue test (Farnsworth,
1943).
(vi) Physician-documented insomnia: Insomnia Severity Index
(Bastien et al., 2001), Athens Insomnia Scale (Soldatos et al.,
2000), or clinical interview.
(vii) Excessive daytime somnolence: Epworth Sleepiness scale
(Johns, 1991; Valencia Garcia et al., 2018) or clinical
interview.
(viii) Restless legs syndrome: diagnosed using clinical interview.
(ix) Sleep apnoea: apnoea-hypopnoea index cut-off 515/h (second-
ary analysis was also performed using cut-off 55/h).
(x) REM sleep without atonia: scored as % tonic and phasic chin
REM on the polysomnographic trace, using either Montreal
scoring (Montplaisir et al., 2010), or % ‘any’ tone using
SINBAR scoring, chin  arm (Frauscher et al., 2012). For
combined stratiﬁcation, we divided each individual’s score by
the mean estimate from their centre.
(xi) Constipation: Uniﬁed MSA Rating Scale (UMSARS) (Wenning
et al., 2004), SCOPA-AUT (Visser et al., 2004), Rome Criteria
(Higgins and Johanson, 2004), or clinical interview.
(xii) Urinary symptoms: UMSARS, SCOPA-AUT, or clinical
interview.
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(xiii) Erectile dysfunction: UMSARS, SCOPA-AUT, or clinical
interview.
(xiv) Orthostatic symptoms: UMSARS, SCOPA-AUT, PD-NMS-
Quest (Chaudhuri et al., 2006), or clinical interview.
(xv) Orthostatic blood pressure: assessed lying and after 1–3min
standing. For illustration/stratiﬁcation purposes only, a cut-
off systolic drop of 410mmHg was used.
(xvi) Cognition, neuropsychological testing: MCI/neurocognitive
disorder diagnosed as abnormal neuropsychological testing
(generally two or more tests abnormal in one or more
domain, adjusted for age and education), plus subjective cog-
nitive complaint, and preserved activities of daily living. We
also assessed predictive value of abnormal cognitive testing,
regardless of reported cognitive symptoms.
(xvii) Cognition, ofﬁce-based diagnosis: Folstein Mini-Mental State
Examination (MMSE) (Folstein et al., 1975) or Montreal
Cognitive Assessment (MoCA) (Nasreddine et al., 2005). For
stratiﬁcation, an education-adjusted MoCA5 26 and
MMSE5 28 were deﬁned as abnormal (for combined analysis,
MoCA given priority, as it has a validated MCI cut-off)
(Nasreddine et al., 2005). For deﬁnition of ofﬁce-based pos-
sible MCI, we also required cognitive complaint/symptoms.
(xviii) Depression: Beck Depression Inventory (Beck et al., 1961),
Geriatric Depression Scale (Yesavage et al., 1982), Patient
Health Questionnaire-9 (Kroenke et al., 2001) or clinical
interview.
(xix) Anxiety: Beck Anxiety Inventory (Beck et al., 1988),
Neuropsychiatric Inventory (Cummings et al., 1994), State-Trait
Anxiety Inventory (Gaudry et al., 1975), Hospital Anxiety and
Depression scale (Zigmond and Snaith, 1983), Leeds Anxiety
Scale (Snaith et al., 1976), and NMS-Quest (Chaudhuri et al.,
2006), Generalized Anxiety Disorder-7 (Spitzer et al., 2006).
(xx) Dopamine-transporter single photon emission tomography
(DAT-SPECT), focusing on the putamen as region of interest.
(xxi) Substantia nigra pars compacta hyperechogenicity measured
by transcranial ultrasound.
Follow-up and disease conversion
All centres prospectively followed patients with in-person evalu-
ation to diagnose phenoconversion to deﬁned parkinsonism
[deﬁned as bradykinesia plus at least one of rigidity or rest
tremor (Postuma et al., 2015b)] or dementia [deﬁned as cogni-
tive impairment on standardized testing with functional impair-
ment (Dubois et al., 2007)]. For patients with parkinsonism as
the primary disease manifestation, the primary diagnosis
(Parkinson’s disease/MSA) was made according to the treating
neurologist. This differential diagnosis incorporated all available
follow-up information (i.e. any patient who was initially diag-
nosed with Parkinson’s disease at phenoconversion but who
was subsequently found to have MSA would be included as
MSA). For dementia conversions, all patients had polysomno-
gram-diagnosed RBD; therefore, they met 2017 criteria for
probable dementia with Lewy bodies with a clinical core symp-
tom plus biomarker loss of REM atonia (McKeith et al., 2017).
One centre (Barcelona) excluded patients with MCI from their
cohort at baseline and delineated de novo MCI as a phenocon-
version. To prevent any resulting bias in conversion risk esti-
mates, we delineated phenoconversion as new parkinsonism or
neuropsychological-examination-diagnosed MCI for this centre
only (and also conducted sensitivity analysis removing that
centre). Survival analysis was done using Kaplan-Meier analysis
to estimate disease risk. For overall analysis, time = 0 was the
ﬁrst baseline in-person evaluation. In analysis of individual vari-
ables, not all variables might have been measured at the same
baseline visit. Therefore, we calculated the interval for each in-
dividual variable (i.e. time = 0 was the ﬁrst evaluation of that
speciﬁc variable). For the stratiﬁcation analysis (and for illustra-
tion in ﬁgures), we deﬁned predictive markers binarily (normal/
abnormal). For those variables without deﬁnable cut-offs for
abnormality within RBD (e.g. REM atonia, age), we stratiﬁed
as above versus below mean values (Table 2). For testing po-
tential prodromal markers, the primary analysis was Cox pro-
portional hazards analysis adjusting for baseline age, sex, and
centre. Each prodromal marker was analysed both as continu-
ous and categorical variables. To facilitate comparison between
variables, we present the categorical analysis (stratiﬁed as dis-
cussed above); note that in all cases, statistical signiﬁcance
(P5 0.05 threshold) was the same for continuous and categor-
ical analyses. Finally, we assessed the predictive value of selected
markers in combination. To increase precision and reliability
only combinations that could be tested in at least three centres,
with 450 patients in each possible combination (i.e. none, one,
or both variables present) were eligible for combined analysis.
On secondary analysis, among convertors who were diagnosed
with Lewy body disease (i.e. excluding MSA), we compared
those who developed dementia as the ﬁrst disease manifestation
versus parkinsonism-ﬁrst conversions (if both were diagnosed
on the same visit, the patient was classiﬁed as dementia-ﬁrst).
Finally, we estimated sample size requirements for a future
neuroprotective trial. This assumed a categorical deﬁnitive
end-point (deﬁned disease phenoconversion), with two
groups (placebo versus a single-dose of active treatment),
two-sided alpha = 0.05, and 80% power. We used time-to-
event analysis (http://www.quesgen.com/SSSurvival.php), for
a 2-year trial, assuming an agent that reduces phenoconver-
sion with HR = 0.5. We calculated sample size for the popu-
lation as a whole, and using stratiﬁcation by prodromal
marker testing, using directly-observed conversion rates, and
also by using the hazard ratio from the current study esti-
mates (i.e. adjusting for centre effects by recalculating the
conversion rate in each single analysis to equal the median
conversion rate in the entire group). For assessment of MDS
prodromal criteria, we included only patients who had sufﬁ-
cient testing to reasonably estimate their % probability,
which was deﬁned as four or more prodromal variables
including at least one of the three highest-speciﬁcity variables
(olfaction, objective motor examination/quantitative testing,
DAT-SPECT); for all calculations, the likelihood ratio of
RBD (130) was included.
Data availability
The original database from the study can be obtained by con-
tacting the ﬁrst author (R.B.P.).
Results
Participants
A total of 1280 patients from 24 centres were included in
this study. Recruitment data from each centre are
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summarized on Table 1. Mean age at baseline was
66.3  8.4 and 82.5% were male. The mean follow-up
duration (between ﬁrst baseline examination and last
contact or disease conversion) was 3.6 years (max-
imum = 19 years), translating to 4890 total person-years
of follow-up.
Overall outcome
During follow-up, 352 (28%) converted to an overt neuro-
degenerative syndrome (Fig. 1). The mean interval between
baseline evaluation and phenoconversion was 4.6  3.5
years. The median time to phenoconversion was 8.0 years,
Table 2 Baseline predictors of neurodegenerative phenoconversion in iRBD
Developed
disease n = 353
Still disease-free
n = 927
Unadjusted HR
(95%CI)
HR, adjusted
age/sex/centre
(95% CI)
Age 67.6  6.9 65.9  8.8 1.52 (1.23–1.88) 1.54 (1.23–1.91)
Sex, % male 83.9 82.0 0.98 (0.73–1.30) 0.93 (0.70–1.24)
UPDRS Part III
Combined: abnormal 62.1% 29.9% 2.70 (2.03–3.60) 3.03 (2.21–4.15)
1987 UPDRS 5.84  4.72 (n = 142) 2.84  3.36 (n = 279) 2.46 (1.75–3.45) 2.75 (1.89–4.01)
MDS-UPDRS 6.26  4.94 (n = 57) 3.12  3.82 (n = 299) 3.48 (2.03–5.97) 3.77 (2.11–6.77)
Quantitative motor abnormal 62.7% (n = 75) 22.7% (n = 198) 3.46 (2.16–5.56) 3.16 (1.86–5.37)
UPDRS Part II
Combined, above mean 56.0% 32.2% 1.62 (1.12–2.36) 2.11 (1.35–3.32)
1987 UPDRS 1.38  1.79 (n = 72) 1.13  1.85 (n = 157) 1.23 (0.76–1.99) 1.29 (0.75–2.22)
MDS-UPDRS 3.33  4.21 (n = 51) 1.87  3.84 (n = 233) 2.94 (1.66–5.20) 4.75 (2.33–9.66)
Olfaction abnormal 78.7% (n = 127) 63.5% (n = 501) 2.33 (1.52–3.58) 2.62 (1.67–4.12)
Olfaction, excluding MSA 80.3% (n = 122) 63.5% (n = 501) 2.54 (1.62–3.98) 2.91 (1.81–4.67)
Colour vision abnormal 52.9% (n = 70) 32.4% (n = 170) 1.62 (1.01–2.56) 1.69 (1.01–2.78)
Insomnia 31.6% (n = 79) 29.9% (n = 328) 0.86 (0.54–1.39) 0.90 (0.54–1.52)
Daytime somnolence 34.6% (n = 263) 29.3% (n = 755) 1.06 (0.82–1.38) 1.16 (0.89–1.51)
Restless legs syndrome 17.2% (n = 169) 17.9% (n = 504) 0.92 (0.61–1.40) 1.06 (0.67–1.68)
Apnoea (AHI5 15) 27.7% (n = 271) 27.4% (n = 811) 1.06 (0.81–1.38) 0.92 (0.70–1.23)
REM %a: above mean 60.0% 47.5% 1.65 (1.13–2.42) 1.54 (1.05–2.27)
Tonic REM % (MTL) 52.6  29.1 (n = 104) 47.3  29.2 (n = 255) 1.41 (0.95–2.08) 1.38 (0.93–2.05)
Phasic REM % (MTL) 32.5  18.3 (n = 80) 30.0  21.5 (n = 170) 1.18 (0.76–1.84) 1.37 (0.84–2.26)
% Any (SINBAR) 65.0  21.1 (n = 18) 59.1  23.7 (n = 91) 2.69 (0.62–11.7) 3.40 (0.75–15.1)
Constipation 56.4% (n = 202) 38.7% (n = 628) 1.69 (1.27–2.23) 1.67 (1.24–2.24)
Urinary dysfunction 34.3 (n = 143) 30.5% (n = 544) 1.20 (0.85–1.69) 1.06 (0.73–1.54)
Erectile dysfunction 63.1% (n = 65) 36.5% (n = 211) 1.89 (1.13–3.21) 2.13 (1.10–4.13)
Orthostatic symptoms 33.6% (n = 119) 28.2% (n = 412) 1.29 (0.88–1.89) 1.41 (0.93–2.13)
Systolic blood pressure drop 14.4  18.6 (n = 87) 6.5  13.7 (n = 267) 1.55 (1.04–2.29) 1.37 (0.90–2.08)
Abnormal office: cognitive test
(regardless of complaint) 53.0% (n = 185) 34.4% (n = 591) 1.63 (1.22–2.18) 1.55 (1.15–2.11)
MoCA 526 24.7  3.2 (n = 84) 25.8  2.9 (n = 346) 1.47 (0.95–2.27) 1.47 (0.93–2.32)
MMSE 528 26.9  3.4 (n = 132) 28.1  1.8 (n = 375) 1.69 (1.20–2.38) 1.58 (1.10–2.28)
Neuropsychological abnormal (regardless of complaint) 60.9% (n = 138) 25.9% (n = 328) 2.09 (1.48–2.94) 1.89 (1.22–2.94)
Mild cognitive impairmentb
Neuropsychological testing 55.4% (n = 121) 16.4% (n = 299) 2.53 (1.77–3.62) 2.37 (1.45–3.88)
MoCA/MMSE 41.7% (n = 151) 17.4% (n = 477) 1.98 (1.43–2.74) 1.91 (1.34–2.73)
Depression 28.8% (n = 226) 25.6% (n = 632) 1.17 (0.87–1.56) 1.20 (0.88–1.63)
Anxiety 22.6% (n = 116) 17.7% (n = 429) 1.46 (0.93–2.27) 1.44 (0.88–2.35)
Substantia nigra ultrasound 64.3% (n = 14) 64.5% (n = 65) 1.14 (0.35–3.72) 1.19 (0.29–4.82)
DAT scan (putamen) abnormal 69.2% (n = 52) 37.3% (n = 193) 2.22 (1.22–4.05) 1.98 (1.05–3.73)
MDS prodromal criteria 92.7% (n = 150) 71.1% (n = 440) 4.52 (2.44–8.35) 5.37 (2.77–10.4)
Continuous variables are presented as mean  standard deviation (n). To allow direct comparisons between markers, all continuous variables are stratified to normal versus
abnormal; for values with no defined abnormal cut-off above (e.g. age) results were stratified as above or below mean values. Hazard ratios are presented according to Cox
proportional hazards analysis performed with logistic regression adjusting for age, sex, and centre.
aEach result is stratified to above or below mean values for that centre. The combined analysis combines tonic/phasic/any tone. Measures for which the confidence intervals do not
cross one (i.e. P5 0.05) are highlighted in bold.
bReference group is normal cognitive testing (regardless of cognitive complaint). Diagnosis of MDS prodromal criteria includes the likelihood ratio of RBD.
AHI = Apnoea–Hypopnea Index; MoCA = Montreal Cognitive Assessment; MMSE = Mini Mental State Examination; MTL = Montreal; SINBAR = Sleep Innsbruck Barcelona.
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with an overall phenoconversion rate of 6.25% per year. The
risk of phenoconversion on Kaplan-Meier analysis was
10.6% after 2 years, 17.9% after 3 years, 31.3% after 5
years, 51.4% after 8 years, 60.2% after 10 years, and
73.5% after 12 years. With regards to disease classiﬁcations,
199 (56.5%) developed parkinsonism as the ﬁrst disease
manifestation [of whom 16 (4.5%) were diagnosed with
probable MSA], and 153 (43.5%) developed dementia ﬁrst.
Predictors of outcome
Kaplan-Meier analysis of selected predictors is illustrated
on Fig. 2. On Cox proportional hazards analysis, adjusting
for age, sex, and centre, numerous measures signiﬁcantly
predicted outcome (Table 2 and Figs 2–4). These included:
(i) quantitative motor testing (HR = 3.16); (ii) standardized
motor examination [HR = 3.03 overall, higher for MDS-
UPDRS (3.77) than UPDRS-III (2.75)]; (iii) olfaction
(HR = 2.62). Predictive value also improved when exclud-
ing MSA patients (HR = 2.91); (iv) MCI, with better pre-
diction using neuropsychological examination (HR = 2.37)
than with ofﬁce-based testing (HR = 1.91); (v) erectile dys-
function (HR = 2.13); (vi) motor symptoms: HR = 2.11,
with better prediction for the MDS-UPDRS-II (HR = 4.75)
than the 1987 UPDRS-II (HR = 1.29); (vii) DAT-SPECT
(HR = 1.98); (viii) neuropsychological testing (regardless
of cognitive complaint) (HR = 1.89); (ix) colour vision
(HR = 1.69); (x) constipation (HR = 1.67); (xi) REM sleep
without atonia (HR = 1.54, on combined analysis only);
(xii) brief ofﬁce-based cognitive tests (regardless of cogni-
tive complaint) (MMSE/MoCA combined HR = 1.55); and
(xiii) age (HR = 1.54 for above versus below mean).
In addition, systolic blood pressure drop at a cut-off of
10mm (HR = 1.55) predicted outcome on unadjusted ana-
lysis, but not after adjusting for age, sex, and centre
(HR = 1.37) (using a cut-off of 20mm, the unadjusted
HR was 1.37 (0.88–2.15) and adjusted HR was 1.20
(0.74–1.91). The MDS prodromal criteria (which combines
numerous variables) predicted outcome with the highest
hazard ratio (HR = 5.37).
By contrast, we saw no signiﬁcant predictive differences
according to sex, insomnia symptoms, daytime somnolence,
restless legs syndrome, apnoea, urinary dysfunction, ortho-
static symptoms, depression, anxiety, or substantia nigra
ultrasound.
Secondary and sensitivity analyses
Among the 336 patients diagnosed with Lewy Body disease
(i.e. excluding MSA), there were relatively few differences
between patients who converted to dementia ﬁrst versus
parkinsonism ﬁrst (Table 3). Age and sex were similar.
All motor measures were similar except for quantitative
motor testing, which was more likely to be abnormal in
those developing dementia ﬁrst (82.4%) than parkinsonism
ﬁrst (47.2%). Olfaction was similar in both groups, as were
all sleep symptoms and polysomnographic variables.
Autonomic symptoms were similar, as was orthostatic
blood pressure drop, depression or anxiety. Although
power was limited, we also saw no differences in propor-
tion of patients with abnormal DAT-SPECT or substantia
nigra ultrasound. The only variables that differed strongly
(all P5 0.001) were those that tested cognition, including
ofﬁce based cognitive testing, neuropsychological examin-
ation, and colour vision testing which predicted only de-
mentia [note that colour vision predominantly tests
visuoperceptual cognition in Parkinson’s disease (Bertrand
et al., 2012)].
Excluding results from centres that already published
data on these predictors did not substantially affect the
hazard ratio. For example, the hazard ratio of UPDRS
excluding Montreal (Postuma et al., 2012) was 3.04,
versus 3.03 for entire group. The hazard ratio of olfaction
excluding both Montreal (Postuma et al., 2011) and
Innsbruck (Mahlknecht et al., 2015) was 2.53, versus 2.62.
Sample size calculations
Based on the time-to-event analysis, we estimated that 366
patients per arm would need to be recruited into a 2-year
trial to have 80% power to ﬁnd a 50% reduction in disease
phenoconversion (i.e. 65 phenoconversion events; Table 4).
Adjusting the study duration altered sample sizes roughly
proportionally to the proportion in duration (e.g. 4-year
trial = 192 per group, 1-year trial = 709 per group). Testing
different effectiveness assumptions, a drug providing 80%
reduction in phenoconversion would require 84 patients
per group (12 phenoconversion events) while a 30% reduc-
tion would require 959 (190 phenoconversion events).
The most powerful single selection procedure (abnormal
quantitative motor testing) reduced sample size to 166–197
patients; however, only 34% of the iRBD population had
abnormal testing and so would be included in such a study.
Figure 1 Kaplan-Meier plot of disease-free survival (i.e.
free of parkinsonism or dementia) among patients with
iRBD.
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Figure 2 Kaplan-Meier plot of disease-free survival of patients with iRBD stratified according to presence of motor and
cognitive markers. Results are presented according to baseline assessment (i.e. patients who develop a de novo marker abnormality over the
course of the follow-up remain in the ‘marker-free’ group). Solid line indicates patients with normal values, dashed line abnormal values. Hazard
ratios (HRs) are with Cox proportional hazards, adjusting for age, sex, and centre, with 95% confidence intervals in parentheses.
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Figure 3 Kaplan-Meier plot of disease-free survival of patients with iRBD stratified according to presence of sleep and psy-
chiatric markers. Solid line indicates patients with normal values, dashed line abnormal values. Hazard ratios (HRs) are with Cox proportional
hazards, adjusting for age, sex, and centre, with 95% confidence intervals in parentheses.
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Figure 4 Kaplan-Meier plot of disease-free survival of patients with iRBD stratified according to presence of special sensory
and autonomic markers. Solid line indicates patients with normal values, dashed line abnormal values. Hazard ratios (HRs) are with Cox
proportional hazards, adjusting for age, sex, and centre, with 95% confidence intervals in parentheses.
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On the other hand, other stratiﬁcation strategies allowed
more inclusions; selecting for abnormal olfaction allowed
67% eligibility with sample size of 247–262 per group, and
selecting those who met the MDS prodromal criteria
allowed 77% eligibility with sample size of 282–301 per
group. Among two-factor combinations, the combination
of olfaction and UPDRS retained 29% eligibility, and re-
sulted in an estimated 15.7% annual conversion rate, trans-
lating into 157 patients per group.
Discussion
In this large multicentre study, we have conﬁrmed the very
high risk of Parkinson’s disease, dementia with Lewy
bodies, and MSA in ‘idiopathic’ RBD, and have conﬁrmed
numerous predictors of outcome. These ﬁndings have im-
plications for potential prevention/early treatment of the
neurodegenerative synucleinopathies.
Risk of disease
As this is the largest study ever performed in iRBD, it has
potentially the most precise estimates of phenoconversion
rates. Overall, we found phenoconversion rates of 6.25%
per year. This is broadly similar, although slightly lower
than some previous estimates, including that of the only
previous multicentre study (which found an 8% annual
conversion; Postuma et al., 2015d). The reason for this
Table 3 Diagnosed Lewy body disease, divided into parkinsonism versus dementia-first
Parkinsonism-first n = 184 Dementia-first n = 146 P-value
Age 67.4  6.6 68.3  7.1 0.23
Sex, % male 81.0 88.4 0.068
UPDRS Part III
Combined: abnormal 60.4% 63.7% 0.64
1987 UPDRS 5.40  4.38 (n = 60) 6.17  4.96 (n = 77) 0.34
MDS-UPDRS 5.56  5.08 (n = 41) 6.36  3.69 (n = 14) 0.53
Quantitative Motor Abnormal 47.2% (n = 36) 82.4% (n = 34) 0.002
UPDRS Part II
Combined, above mean 50.0% 61.7% 0.22
1987 UPDRS 1.44  1.84 (n = 35) 1.10  1.46 (n = 34) 0.51
MDS-UPDRS 2.38  2.75 (n = 34) 5.60  6.12 (n = 15) 0.27
Olfaction abnormal 75.7% (n = 70) 86.5% (n = 52) 0.13
Colour vision abnormal 30.3% (n = 33) 73.5% (n = 34) 50.001
Insomnia 26.1% (n = 46) 32.1% (n = 28) 0.58
Daytime somnolence 28.6% (n = 133) 40.4% (n = 114) 0.051
Restless legs syndrome 21.1% (n = 95) 11.3% (n = 62) 0.11
Apnoea (AHI5 15) 26.8% (n = 158) 31.9% (n = 94) 0.98
REM %: above mean 57.4% 64.3% 0.47
Tonic REM % (MTL) 50.2  28.1 (n = 60) 56.3  31.6 (n = 39) 0.33
Phasic REM % (MTL) 29.8  19.9 (n = 42) 35.8  16.6 (n = 34) 0.16
% Any (SINBAR) 66.4  19.9 (n = 13) 61.2  26.0 (n = 5) 0.70
Constipation 56.8% (n = 111) 57.5% (n = 80) 0.92
Urinary dysfunction 29.4% (n = 85) 39.6% (n = 53) 0.22
Erectile dysfunction 52.8% (n = 36) 75.0% (n = 28) 0.069
Orthostatic symptoms 28.4% (n = 67) 39.1% (n = 46) 0.23
Systolic blood pressure drop 12.7  15.7 (n = 44) 17.0  21.9 (n = 37) 0.32
Abnormal office: cognitive test (regardless of complaint) 43.2% 65.2% 0.003
MoCA 25.8  2.6 (n = 49) 22.6  3.5 (n = 30) 50.001
MMSE 27.8  1.7 (n = 57) 26.4  3.3 (n = 70) 0.002
Neuropsychological abnormal (regardless of complaint) 29.8% (n = 57) 86.8% (n = 76) 50.001
Mild cognitive impairment
Neuropsychological testing 25.9% (n = 54) 84.1% (n = 63) 50.001
MoCA/MMSE 30.1% (n = 73) 56.9% (n = 72) 0.001
Depression 28.6% (n = 119) 32.6% (n = 92) 0.53
Anxiety 22.5% (n = 71) 28.2% (n = 39) 0.52
Substantia nigra ultrasound 60.0% (n = 10) 66.7% (n = 3) 0.84
DAT scan (putamen) abnormal 70.3% (n = 37) 71.4% (n = 14) 0.94
P-values are calculated with student t-test for continuous variables and 2 test for categorical variables. Note that seven patients from Barcelona who converted to MCI but not yet to
parkinsonism or dementia are not included in this analysis.
AHI = Apnoea–Hypopnea Index; MoCA = Montreal Cognitive Assessment; MMSE = Mini Mental State Examination; MTL = Montreal; SINBAR = Sleep Innsbruck Barcelona.
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slightly lower estimate is unclear. One explanation could
have been secular change; as a disease becomes increasingly
recognized, milder/earlier cases (with lower conversion
rates) come to attention. However, we found no clear evi-
dence for this; those diagnosed after 2010 had a 19.2% 3-
year risk of disease, compared to 16.9% among those
before. It could also be possible that newer centres in the
RBD Study Group might have different (i.e. more permis-
sive) diagnostic procedures, which would imply increasing
proportions of patients without true synucleinopathy.
However, centres who participated in the original multi-
centre study did not have a higher risk than those without
(e.g. original centres’ 3-year risk = 16.8%, versus 21.6%
for new centres). We did note that annualized disease risk
appeared to be lower from Years 0 to 2 than for subse-
quent years. This may indicate a potential selection bias; if
examiners were reluctant to recruit patients who appeared
on the threshold of parkinsonism or dementia, risk would
be systematically underestimated (since patients would have
to ﬁrst develop mild signs, then full disease).
Another potentially key factor for phenoconversion may
be the frequency and intensity of follow-up. Many patients
do not recognize symptoms of parkinsonism/cognitive im-
pairment, and are diagnosed only on in-person systematic
examination. A striking illustration of the importance of
follow-up intensity is the Montreal experience. In their
2009 report, which included patients followed clinically/
ad hoc, conversion risk at 5 years was 18% (Postuma
et al., 2009). However, 6 years later, a study from the
same centre, this time concentrating exclusively upon pa-
tients followed systematically by a movement disorders spe-
cialist and neuropsychologist, found a 5-year risk of 47%
(Postuma et al., 2015c). Moreover, we may see evidence of
this in our cohort, as conversion estimates were higher
when they were calculated starting from the ﬁrst date of
intensive in-person examination of Parkinson’s disease/de-
mentia risk factors (olfaction, UPDRS, cognitive exam, etc).
For example, if conversion risk is tracked from perform-
ance of the ﬁrst UPDRS Part III neurologist examination (a
potential sign that more intensive follow-up has com-
menced), the estimated annual risk of conversion rises
from 6.3% to 7.1%; see Table 4 for the potential effects
of this on observed versus estimated sample size calcula-
tions. This might imply that a clinical trial with intensive
Table 4 Sample size calculations for neuroprotective trials
Population Proportion of
sample abnormal, %
Observed
conversion rate, %
Adjusted conversion rate
(adjusted for centre), %
Sample size per
group - observed/
adjusted
All RBD 100 6.25 6.25 366/366
Age at least 55 92 6.32 6.32 363/363
UPDRS III (combined 1987 and MDS) 38 12.7 11.1 190/214
Quantitative motor test (majority
abnormal)
34 14.7 12.2 166/197
Olfaction 67 9.52 8.93 247/262
Colour vision 38 11.9 8.47 201/275
MCI (office-based) 23 13.1 9.09 184/258
MCI (neuropsychology) 28 16.3 11.4 152/210
DAT scan 44 11.5 10.9 208/219
Constipation 56 8.33 8.07 279/288
Either elevated UPDRS or MCI on
neuropsychology
53 10.2 10.2 232/232
Elevated UPDRS and MCI (neuropsych.
only)
13 17.5 14.8 143/166
Elevated UPDRS and MCI anya 14 16.3 14.3 152/171
Either elevated UPDRS or MCI anya 55 11.8 10.3 203/230
UPDRS and olfaction abnormal 29 15.7 15.7 157/157
UPDRS and constipation 18 15.4 14.3 160/171
Olfaction and constipation 29 10.5 9.15 226/257
Olfaction and MCIa 14 15.7 13.3 157/183
Olfaction and either UPDRS or MCIa 39 14.7 12.4 166/195
Meets MDS Prodromal Criteria 77 8.24 7.69 282/301
Sample size is calculated using a time-to-event analysis for a disease phenoconversion to either dementia or parkinsonism as the primary outcome. The calculation is for a 2-year trial,
with accrual set at 0 (i.e. all patients are followed for exactly 2 years). The assumption is for a disease-modifying agent that reduces HR to 0.5 (65 phenoconversion events), with
power = 80% at 50.05 (two-tailed). For stratification, patients are included if they are abnormal for that test (or combination of tests). Note that the observed rate includes only
those centres that performed the evaluation, at the time that the marker was first evaluated. The adjusted rate was calculated by dividing the overall observed rate in all centres that
performed the marker (both normal and abnormal tests) by the median rate in all centres (thereby estimating the rate that would have been seen if all centres performed the test).
Although the observed rate is not adjusted for centre effects, it may better reflect experience in clinical trials, in which follow-up is performed more intensively (see ‘Discussion’
section).
aIn these cases, MCI can be defined as either an abnormal neuropsychological test or office-based test, plus cognitive complaint. If both were performed and contradict, the
neuropsychological test result takes precedence.
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periodic evaluations may ﬁnd a higher conversion risk than
observed in this study. Regardless of the conversion rate, it
is clear that the large majority of idiopathic RBD patients
in fact have prodromal synucleinopathy. So, while the term
‘idiopathic’ RBD is used here, we recognize that few pa-
tients are truly ‘idiopathic’ in the original sense of the term
(i.e. unclear cause), and other terms such as ‘clinically iso-
lated’ RBD may be more appropriate (Hogl et al., 2018).
Predictive markers
Although comparisons of hazard ratios across different pre-
dictors should be made with caution (because centres mea-
sured different variables), it nonetheless suggests numerous
ﬁndings of interest. When analysed as a binary diagnostic
test, there was no clear advantage of DAT-SPECT over
either the UPDRS or quantitative motor testing (note that
both DAT-SPECT and quantitative motor tests were deﬁned
by each centre as normal/abnormal with no harmonization
procedures; harmonization might increase the hazard ratio).
Note that this ﬁnding may be unique to iRBD patients, who
have an extremely high prevalence of underlying synucleino-
pathy; in the general population, non-speciﬁc causes of
motor slowing on quantitative motor tests (e.g. arthritis)
may inﬂuence estimates more (Keezer et al., 2016; Jennings
et al., 2017). Regardless, these quantitative motor tests were
simple ofﬁce-based tests that required 55 min to administer.
Clearly these are strong candidates for selecting patients for
future neuroprotective trials, and could even obviate the
need for sophisticated imaging techniques if simpler trial
design is required. This ﬁnding illustrates both the need to
improve imaging techniques for prodromal disease and the
considerable future potential for more precise quantitative
motor markers (e.g. wearable or smartphone-based sensors).
It is not surprising that the highest hazard ratios were for
motor and cognitive measures, since these are the primary
means by which parkinsonism and dementia are deﬁned;
however, the high performance of olfactory testing as a
predictor is notable, as it is also easily tested in ofﬁce set-
tings. Finally, no test appeared to be able to ‘rule out’
phenoconversion; many of those with normal testing still
went on to develop parkinsonism and dementia. For ex-
ample, the highest negative predictive value was seen for
the MDS prodromal criteria, but even among those nega-
tive for criteria, 5% phenoconverted at 3 years, 13% at 5
years, and 27% at 8 years (note that analysis is at baseline
only, and presumably many of these patients would have
developed abnormal markers before phenoconversion).
Dementia-first versus
parkinsonism-first
The comparison between dementia-ﬁrst and parkinsonism-
ﬁrst phenoconvertors was notable for the similarity in pre-
dictive value between markers. Motor variables were highly
predictive of dementia as well as parkinsonism (and for
quantitative motor assessment, even more predictive of
dementia than parkinsonism). This ﬁnding is consistent
with previous studies which documented a longer/slower-
progressing motor prodromal interval in dementia-ﬁrst than
parkinsonism-ﬁrst convertors (Postuma et al., 2012); if
their motor prodromal interval is longer in prodromal de-
mentia patients, they would be more likely to be abnormal
on a cross-sectional test. Overall, the only clear differentiat-
ing variable between dementia and parkinsonism was cog-
nition itself. It is unclear whether the conversion to
dementia versus parkinsonism ﬁrst is related to a different
‘top-down’ synuclein spread upwards to cortex before the
substantia nigra (Adler and Beach, 2016), or to effects of
co-morbid pathology [i.e. if a person with RBD has co-
morbid amyloid cortical pathology, even modest cortical
deposition of synuclein could trigger rapid cortical neuro-
degeneration resulting in a dementia-ﬁrst phenotype
(Chetelat et al., 2013)].
Sample size
We calculated the sample size requirements for a deﬁnitive
neuroprotective trial, using phenoconversion as a categorical
endpoint. Overall, sample sizes for a 2-year trial with
HR = 0.5 ranged from 150 to 360 patients per group. In
general, stratiﬁcation strategies could decrease sample sizes,
at the cost of reduced generalizability and less efﬁcient re-
cruitment. Of the selection strategies, the two most efﬁcient
appeared to be olfaction, which reduced sample size by
28.5% while retaining 67% of the sample as potential trial
candidates, and the MDS prodromal criteria, which reduced
sample size by 17.8% while retaining 77% of the sample. Of
course, exact sample size calculations will depend on the
speciﬁcs of a clinical trial; nevertheless, the fact that 24 cen-
tres combined to produce these estimates can provide some
conﬁdence for trial planners that sample sizes will be repre-
sentative of the global experience. Notably, the total sample
size for a future neuroprotective trial is less than the number
of participants who were recruited to this study. So, it ap-
pears that a complete trial-ready population already exists in
the centres of the International RBD Study Group.
Limitations and strengths
Some limitations of this study should be pointed out. First,
this study is an amalgam of the research experience of 24
different centres; there was not a single protocol for testing
predictors of disease, and protocols differed greatly between
centres in terms of depth, follow-up intensity, predictors as-
sessed, and methods/cut-offs for assessing them. Therefore,
the predictive data will not be fully comparable to a single
clinical trial setting, which would have a single testing proto-
col. Second, protocols for recruiting MCI varied; 23 of 24
centres recruited patients at baseline with MCI, but the lar-
gest centre (Barcelona) did not. There is no perfect way to
harmonize these completely; for the primary analysis we
elected to allow the Barcelona group to deﬁne disease con-
version as de novo MCI, to prevent underestimation of
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disease risk (i.e. if patients with MCI were systematically
excluded at baseline, then patients developing dementia
would have to cycle from normal cognition through MCI
to dementia, artiﬁcially prolonging disease-free time).
However, if conversion from normal cognition to MCI
were faster than from MCI to dementia/parkinsonism, dis-
ease risk might be overestimated. Regardless, excluding
Barcelona data had almost no effect on risk estimates
(median conversion time = 8.01 years with and 8.00 with-
out). Third, hazard ratio comparisons between the different
markers should be made with caution, as different centres
(with potentially different conversion rates) tested different
markers using different techniques (note that the results are
adjusted for centre, which helps mitigate centre effects).
Fourth, the amplitude of the hazard ratio observed in this
study should not be extrapolated to the general population.
When using RBD patients, the baseline risk of disease is so
high that ceiling effects on hazard ratios occur [for illustra-
tion of this effect, see supplemental methods of Berg et al.
(2015)]. Similarly, the effect of very long latency prodromal
markers (e.g. autonomic dysfunction, olfaction, substantia
nigra ultrasound) may be masked by ﬂoor effects; if a
marker preceded RBD in almost all cases, and almost all
RBD patients have prodromal synucleinopathy, there
would be little apparent predictive value of that marker in
this population. Fifth, RBD in Parkinson’s disease marks a
‘diffuse-malignant’ subtype of Parkinson’s disease
(Fereshtehnejad et al., 2015), implying that our hazard
ratio ﬁndings will not completely generalize to those
Parkinson’s disease and dementia with Lewy bodies cases
who have no RBD. Sixth, note that our markers were
tested at baseline only; repeated marker testing would
allow assessment of evolution of prodromal markers over
time. Seventh, although sample size is large in this trial,
some markers were assessed by only a few centres, and so
their corresponding conﬁdence intervals can be wide. Eighth,
the ﬁnal neurodegenerative disease diagnosis of all patients
in this study was clinical, according to best impression of the
treating neurologist; it is likely that some patients diagnosed
with Parkinson’s disease will eventually be discovered to
have MSA, and vice versa. Finally, the number of patients
with very long duration follow-up remains limited (e.g. 28
still-disease-free patients have been followed for 412 years);
therefore, we cannot determine whether disease risk changes
over very long disease durations.
In conclusion, we conﬁrmed a high risk of phenoconver-
sion to overt neurodegenerative disease in RBD and found
numerous predictors of phenoconversion. As new disease-
modifying treatments are being developed for neurodegen-
erative synucleinopathies, RBD patients are ideal candidates
for neuroprotective trials.
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